Rocket


Overview
Financials
News + Filings





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Kairos Pharma, LTD.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21
   S-1S-1
Revenues  0.10.2
            Revenue growth  -52.5% 
Cost of goods sold  0.61.9
Gross profit  -0.5-1.8
            Gross margin  -556.3%-961.7%
Selling, general and administrative   [+]0.51.8
Other operating expenses  -0.4-1.6
EBITDA   [+]-0.3-1.7
            EBITDA margin  -288.5%-954.6%
Depreciation  0.20.1
EBITA  -0.4-1.8
            EBITA margin  -472.4%-1008.2%
Amortization of intangibles  0.20.1
EBIT   [+]-0.6-1.9
            EBIT margin  -656.3%-1061.7%
Other income (expense), net  -0.5-0.2
Pre-tax income  -1.1-2.1
Income taxes  0.00.0
            Tax rate  0.0%0.0%
Net income  -1.1-2.1
            Net margin  -1206.9%-1172.1%
   
Basic EPS   [+]($0.10)($0.23)
Diluted EPS   [+]($0.10)($0.23)
   
Shares outstanding (basic)   [+]10.29.2
Shares outstanding (diluted)   [+]10.29.2
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy